Shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD – Get Free Report) have been given an average recommendation of “Moderate Buy” by the sixteen analysts that are presently covering the company, Marketbeat Ratings reports. Five equities research analysts have rated the stock with a hold rating and eleven have given a buy rating to the company. The average 12 month price target among analysts that have updated their coverage on the stock in the last year is $25.56.
Several equities analysts have issued reports on ACAD shares. Morgan Stanley lowered ACADIA Pharmaceuticals from an “overweight” rating to an “equal weight” rating and dropped their price target for the company from $28.00 to $20.00 in a research note on Wednesday. Royal Bank of Canada reduced their price objective on ACADIA Pharmaceuticals from $29.00 to $26.00 and set an “outperform” rating for the company in a research note on Wednesday. UBS Group dropped their price objective on ACADIA Pharmaceuticals from $25.00 to $23.00 and set a “buy” rating on the stock in a report on Thursday. Citigroup decreased their target price on ACADIA Pharmaceuticals from $30.00 to $23.00 and set a “buy” rating on the stock in a research note on Thursday. Finally, Bank of America reduced their price objective on ACADIA Pharmaceuticals from $26.00 to $22.00 and set a “neutral” rating on the stock in a research report on Friday, May 10th.
View Our Latest Analysis on ACAD
Institutional Trading of ACADIA Pharmaceuticals
ACADIA Pharmaceuticals Price Performance
Shares of ACADIA Pharmaceuticals stock opened at $15.63 on Monday. The business has a fifty day simple moving average of $16.64 and a two-hundred day simple moving average of $18.89. ACADIA Pharmaceuticals has a 1 year low of $14.55 and a 1 year high of $32.59. The company has a market capitalization of $2.58 billion, a price-to-earnings ratio of -1,563.00 and a beta of 0.38.
ACADIA Pharmaceuticals (NASDAQ:ACAD – Get Free Report) last released its earnings results on Tuesday, August 6th. The biopharmaceutical company reported $0.20 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.18 by $0.02. ACADIA Pharmaceuticals had a negative return on equity of 0.41% and a negative net margin of 0.21%. The firm had revenue of $241.96 million for the quarter, compared to analysts’ expectations of $235.95 million. During the same quarter in the previous year, the business posted $0.01 earnings per share. The business’s revenue for the quarter was up 46.4% on a year-over-year basis. As a group, equities analysts anticipate that ACADIA Pharmaceuticals will post 0.58 earnings per share for the current fiscal year.
About ACADIA Pharmaceuticals
ACADIA Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome.
See Also
- Five stocks we like better than ACADIA Pharmaceuticals
- How to Know if a Stock Pays Dividends and When They Are Paid Out
- Cassava Sciences: A Hot Stock to Trade, Invest, or Avoid?
- 3 Small Caps With Big Return Potential
- MarketBeat Week in Review – 8/5 – 8/9
- Learn Technical Analysis Skills to Master the Stock Market
- The Cannabis Sector: Profitability Takes Center Stage
Receive News & Ratings for ACADIA Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ACADIA Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.